Thrombolytic therapy in acute MI. Weighing the risks and benefits.
The underlying cause of acute myocardial infarction can now be effectively treated with thrombolytic agents, thereby increasing myocardial salvage and reducing mortality. Clinicians should always be aware of the risk-to-benefit ratio in treating patients with thrombolytic agents and treat each patient on an individual basis.
Ro
K G
KG
Department of Internal Medicine, University of Texas Health Science Center, Houston.
Anderson
H V
HV
D000208:Acute Disease; D016255:Anistreplase / Q000008:administration & dosage; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
D016255:Anistreplase; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D001241:Aspirin